SciELO - Scientific Electronic Library Online

 
vol.134 número4Poluição do ar e doenças respiratórias: estudo ecológico de série temporalNíveis de pressão arterial e índice de massa corporal em adultos brasileiros com síndrome de Down índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Sao Paulo Medical Journal

versão impressa ISSN 1516-3180versão On-line ISSN 1806-9460

Resumo

MARCOLINO, Milena Soriano et al. Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis. Sao Paulo Med. J. [online]. 2016, vol.134, n.4, pp.322-329.  Epub 18-Jul-2016. ISSN 1806-9460.  https://doi.org/10.1590/1516-3180.2016.0019260216.

CONTEXT AND OBJECTIVE:

Randomized clinical trials have shown that the new oral anticoagulants have at least similar impact regarding reduction of thromboembolic events, compared with warfarin, with similar or improved safety profiles. There is little data on real costs within clinical practice. Our aim here was to perform economic analysis on these strategies from the perspective of Brazilian society and the public healthcare system.

DESIGN AND SETTING:

Cost-minimization analysis; anticoagulation clinic of Hospital Municipal Odilon Behrens, Belo Horizonte, MG, Brazil.

METHODS:

Patients at the anticoagulation clinic were recruited between August and October 2011, with minimum follow-up of four weeks. Operational and non-operational costs were calculated and corrected to 2015.

RESULTS:

This study included 633 patients (59% women) of median age 62 years (interquartile range ­49-73). The mean length of follow-up was 64 ± 28 days. The average cost per patient per month was $ 54.26 (US dollars). Direct costs accounted for 32.5% of the total cost. Of these, 69.5% were related to healthcare professionals. With regards to indirect costs, 52.4% were related to absence from work and 47.6% to transportation. Apixaban, dabigatran and rivaroxaban were being sold to Brazilian public institutions, on average, for $ 49.87, $ 51.40 and $ 52.16 per patient per month, respectively, which was lower than the costs relating to warfarin treatment.

CONCLUSION:

In the Brazilian context, from the perspective of society and the public healthcare system, the cumulative costs per patient using warfarin with follow-up in anticoagulation clinics is currently higher than the strategy of prescribing the new oral anticoagulants.

Palavras-chave : Anticoagulants; Warfarin; Atrial fibrillation; Costs and cost analysis; Public health.

        · resumo em Português     · texto em Inglês     · Inglês ( pdf )